One in 8 patients with ACI experience ultra-early neurological deterioration during ambulance transport and initial evaluation at the emergency department.
A team of investigators sought to assess the efficacy and safety of cilostazol vs aspirin, both with and without probucol, a cholesterol-lowering agent, in Asian patients with ischemic stroke.
Only patients transported via EMS were enrolled, suggesting that these findings are limited to those with more severe blunt head injury vs those who self-present to the emergency department.
Although spot sign predicted ICH expansion, it proved to be a less robust diagnostic marker than demonstrated by previous single-center cohort studies.
Risk for symptomatic intracranial hemorrhage after endovascular treatment for acute ischemic stroke is significantly higher in real-world practice than rates reported by clinical trials.
Compared with other sources of ICH, those associated with arteriovenous malformations had lower odds of death.
Intracranial atherosclerosis was lower in patients with migraine compared with those without migraine.
Patients receiving treatment with vitamin K antagonists (VKA) or antiplatelet agents face a significantly increased risk of mortality within 24 hours of intracranial hemorrhage.
Concomitant use of oral anticoagulants contributed to a significantly higher increased risk for ICH.
The idea of low-dose tPA will likely not be abandoned despite recent findings.
Risk factors differ from ischemic stroke.
REVERSE-AD is an ongoing phase 3 cohort study evaluating the reversal effects of idarucizumab on dabigatran.
Treatment with IV tPA appeared safe and feasible with stroke onset confirmation from MRI.
Surprisingly, multiple types of stroke were associated with a greater risk of seizure than TBI.
Patients with symptoms of TIA should undergo brain imaging to rule out ICH prior to antithrombotic therapy.
The study did not establish whether early intervention improves outcomes.
Compared to standard treatment with IV tPA, endovascular thrombectomy resulted in better functional outcomes at 90 days.
Treatment of intracerebral hemorrhage after thrombolysis did not result in reduced mortality or expansion of the hematoma.
A simple blood test may indicate risk of intracerebral hemorrhage and post-stroke outcomes.
NOACs are prescribed to patients with lower stroke risk compared to those prescribed Warfarin.
Those treated with a stent were twice as likely to suffer a stroke or transient ischemic attack compared to those treated with medication alone.
Those taking dabigatran (Pradaxa) had higher risk of major bleeds, including gastrointestinal bleeding.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Online Family Problem-Solving Program May Improve Behavioral Outcomes in Older Children With TBI
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes